Get the Stockscreener App
1.04
2.97%
0.03
After Hours:
1.04
Iridex Corp stock is traded at $1.04, with a volume of 102.43K.
It is up +2.97% in the last 24 hours and down -1.89% over the past month.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
See More
Previous Close:
$1.01
Open:
$1
24h Volume:
102.43K
Relative Volume:
0.48
Market Cap:
$18.10M
Revenue:
$52.68M
Net Income/Loss:
$-4.44M
P/E Ratio:
-3.9514
EPS:
-0.2632
Net Cash Flow:
$-2.26M
1W Performance:
-0.95%
1M Performance:
-1.89%
6M Performance:
+9.46%
1Y Performance:
+6.12%
1-Day Range:
$0.98
$1.045
1-Week Range:
$0.98
$1.045
52-Week Range:
$0.8688
$1.6481
Iridex Corp Stock (IRIX) Company Profile
Name
Iridex Corp
Sector
Industry
Phone
(650) 940-4700
Address
1212 TERRA BELLA AVE, MOUNTAIN VIEW, CA
Compare IRIX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRIX
Iridex Corp
|
1.04 | 17.58M | 52.68M | -4.44M | -2.26M | -0.2632 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Iridex Corp Stock (IRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-17 | Resumed | ROTH Capital | Buy |
| Dec-21-16 | Initiated | ROTH Capital | Buy |
| Jan-26-16 | Initiated | Singular Research | Buy |
| Jan-03-07 | Initiated | First Albany | Buy |
Iridex Corp Stock (IRIX) Latest News
Iridex CFO Romeo Dizon buys $5,004 in company stock - Investing.com
Iridex CFO Romeo Dizon buys $5,004 in company stock By Investing.com - Investing.com India
IRIDEX Corp (IRIX) CFO adds 5,004 common shares in open-market buy - Stock Titan
IRIDEX Trades Around $1 Following Holiday, Eye-Care Firm Faces Next Challenges - Bez Kabli
IRIX Stock Up 4% As Q1 Loss Narrows Y/Y on Glaucoma Product Growth - Yahoo Finance
IRIDEX Corporation (IRIX) Q1 2026 Earnings Surge: EPS $-0.03 vs $-0.07 ForecastGross Profit Margin - Newser
IRIDEX Corporation (NASDAQ:IRIX) Q1 2026 Earnings Call Transcript - Insider Monkey
IRIDEX Corp (IRIX) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Growth Initiatives - GuruFocus
IRIDEX Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Iridex Beats Profit Forecasts on Cost Cuts Amidst Revenue Dip - BriefGlance
Iridex Q1 2026 Earnings Call: Complete Transcript - Benzinga
IRIDEX earnings beat by $0.02, revenue fell short of estimates - Investing.com
IRIDEX Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Is IRIDEX (IRIX) a Value Trap After Q1 2026? EPS -$0.03 Beats (e - GuruFocus
Iridex Corp (NASDAQ:IRIX) Q1 Loss Narrower Than Expected, Glaucoma Portfolio Strengthens - ChartMill
Iridex posts narrower-than-feared Q1 loss driven by cost cuts; Shares up 4% - Investing.com South Africa
Iridex Reports Q1 2026: Revenue $11.8M, Gross Profit $4.7M, Net Loss $0.5M - TradingView
IRIDEX CORP 1Q 2026: Revenue $11.8M, EPS $(0.03) — 10-Q Summary - TradingView
IRIDEX (NASDAQ: IRIX) narrows quarterly loss as margins tighten - Stock Titan
Iridex (NASDAQ: IRIX) Q1 loss narrows as 2026 outlook reaffirmed - Stock Titan
Iridex: Q1 Earnings Snapshot - marketscreener.com
Iridex Reports First Quarter 2026 Financial Results - Yahoo Finance
IRIDEX Corp stock (US4627191006): eye-care specialist draws attention after FDA clearance and strate - AD HOC NEWS
IRIDEX Corp (IRIX) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... By GuruFocus - Investing.com Canada
IRIDEX Corp expected to post a loss of 7 cents a shareEarnings Preview - TradingView
IRIDEX Corp stock (US4627191006): Ophthalmology device maker with recent market activity - AD HOC NEWS
Earnings Preview: IRIDEX to Report Financial Results Post-market on May 19 - Moomoo
IRIDEX Corp stock (US4627191006): Recent 1.94% gain on Nasdaq - AD HOC NEWS
MSN Money - MSN
The shareholder friendly policies at IRIDEX Corporation (IRIX) | Q4 2025: EPS Beats ForecastsPro Level Trade Signals - Newser
What IRIDEX Corporation (IRIX) does that makes it resilient (Breakdown Watch) 2026-05-07Rounding Top - Newser
Iridex to Report First Quarter 2026 Financial Results on May 19, 2026 - The Manila Times
Iridex sets May 19 investor call with Q1 results after close - Stock Titan
Iridex (NASDAQ: IRIX) schedules 2026 meeting on board, pay, auditor - Stock Titan
[ARS] IRIDEX CORP SEC Filing - Stock Titan
IRIDEX Corporation (IRIX) Stock: What Affects Its Direction | Q4 2025: Profit SurprisesShort Interest - Cổng thông tin điện tử Tỉnh Sơn La
The Zacks Analyst Blog Microsoft, AbbVie, BHP, CBL & Associates Properties and IRIDEX - Zacks Investment Research
IRIDEX Corporation (IRIX) Stock Cash Trade (Breakout Watch) 2026-04-18Earnings Season - newser.com
IRIDEX Corporation (IRIX) Stock Outlook | Q4 2025: EPS Tops ViewsCatalyst Event - newser.com
Aug Reactions: Is IRIDEX Corporation forming a double bottomGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Should I Buy IRIDEX Corporation (IRIX) Stock in 2026 | Price at $1.01, Down 1.94%Small Cap Breakout - newser.com
Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology - The Manila Times
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Wondering what's happening in today's after-hours session? - ChartMill
Iridex partners with EyeProGPO for retina laser distribution - Investing.com
More than 1,800 eye care members gain pricing access to Iridex lasers - Stock Titan
IRIX Should I Buy - Intellectia AI
IRIX.O Technical Analysis & Stock Price Forecast - Intellectia AI
IRIX.O PE Ratio & Valuation, Is IRIX.O Overvalued - Intellectia AI
IRIDEX Corporation: Innovative Ophthalmic Laser Solutions for Glaucoma and Retinal Diseases - Minichart
IRIDEX (NASDAQ: IRIX) 10% holder gets interest paid in stock - Stock Titan
Iridex Corp Stock (IRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iridex Corp Stock (IRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dizon Romeo R | Chief Financial Officer |
Feb 17 '26 |
Buy |
1.34 |
2,200 |
2,942 |
119,890 |
| Dizon Romeo R | Chief Financial Officer |
Feb 12 '26 |
Buy |
1.43 |
1,500 |
2,145 |
117,690 |
| Dizon Romeo R | Chief Financial Officer |
Feb 10 '26 |
Buy |
1.46 |
1,000 |
1,460 |
116,190 |
| Dizon Romeo R | Chief Financial Officer |
Feb 03 '26 |
Buy |
1.38 |
2,500 |
3,450 |
115,190 |
| Dizon Romeo R | Chief Financial Officer |
Jan 29 '26 |
Buy |
1.44 |
1,101 |
1,588 |
112,690 |
| Dizon Romeo R | Chief Financial Officer |
Jan 28 '26 |
Buy |
1.46 |
1,300 |
1,898 |
111,589 |
| Dizon Romeo R | Chief Financial Officer |
Jan 27 '26 |
Buy |
1.48 |
3,385 |
5,009 |
110,289 |
| Dizon Romeo R | Chief Financial Officer |
Jan 26 '26 |
Buy |
1.52 |
1,243 |
1,889 |
106,904 |
| Dizon Romeo R | Chief Financial Officer |
Jan 23 '26 |
Buy |
1.48 |
5,221 |
7,716 |
105,661 |
| Dizon Romeo R | Chief Financial Officer |
Jan 21 '26 |
Buy |
1.50 |
2,159 |
3,233 |
100,440 |
1.27%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):